Literature DB >> 813144

Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease.

H L Greene, A E Slonim, J A O'Neill, I M Burr.   

Abstract

The clinical and biochemical abnormalities associated with Type 1 glycogen-storage disease can be reversed by avoidance of hypoglycemia and secondary hormonal flux. Three patients with Type 1 disease were treated with intragastric infusions of a high glucose formula at night with three-hour starch feedings during the day. This regimen stabilized blood glucose levels above 70 mg per deciliter and decreased serum uric acid, triglyceride, lactate and serum oxalacetic transaminase levels, as well as hepatic size, in all patients. Increased linear growth rate (mean 1 cm per month) was associated with a decrease in mean plasma glucagon (from 190 to 40 pg per milliliter) and an increase in mean plasma insulin (from 19 to 43 muU per milliliter, [two patients]). These changes occurred within four weeks of beginning of treatment and continued with home treatment for 13 months. No complications resulted from tube placement daily by the patients. Type 1 disease can be managed by nighttime intragastric feeding and frequent daytime high starch meals.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 813144     DOI: 10.1056/NEJM197602192940805

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  50 in total

1.  Variability of renal length in type I glycogen storage disease.

Authors:  Y T Chen; K A Feinstein; R A Coleman; E L Effmann
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

Review 2.  Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.

Authors:  Janice Y Chou; Hyun Sik Jun; Brian C Mansfield
Journal:  Nat Rev Endocrinol       Date:  2010-10-26       Impact factor: 43.330

3.  Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice.

Authors:  Wai Han Yiu; Chi-Jiunn Pan; Paul A Mead; Matthew F Starost; Brian C Mansfield; Janice Y Chou
Journal:  J Hepatol       Date:  2009-02-05       Impact factor: 25.083

Review 4.  Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease.

Authors:  Janice Y Chou; Brian C Mansfield
Journal:  Hum Mutat       Date:  2008-07       Impact factor: 4.878

5.  Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.

Authors:  Young Mok Lee; Hyun Sik Jun; Chi-Jiunn Pan; Su Ru Lin; Lane H Wilson; Brian C Mansfield; Janice Y Chou
Journal:  Hepatology       Date:  2012-08-27       Impact factor: 17.425

6.  Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy.

Authors:  Wai Han Yiu; Young Mok Lee; Wen-Tao Peng; Chi-Jiunn Pan; Paul A Mead; Brian C Mansfield; Janice Y Chou
Journal:  Mol Ther       Date:  2010-04-13       Impact factor: 11.454

7.  Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.

Authors:  Goo-Young Kim; Young Mok Lee; Joon Hyun Kwon; Jun-Ho Cho; Chi-Jiunn Pan; Matthew F Starost; Brian C Mansfield; Janice Y Chou
Journal:  Mol Genet Metab       Date:  2017-01-10       Impact factor: 4.797

8.  Glucose production rates in type 1 glycogen storage disease.

Authors:  J E Collins; K Bartlett; J V Leonard; A Aynsley-Green
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

Review 9.  Glycogen storage disease: recommendations for treatment.

Authors:  J Fernandes; J V Leonard; S W Moses; M Odièvre; M di Rocco; J Schaub; G P Smit; K Ullrich; P Durand
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

10.  Plasma and lipoprotein fatty acid composition in glycogen storage disease type I.

Authors:  E Levy; J Letarte; G Lepage; L Thibault; C C Roy
Journal:  Lipids       Date:  1987-06       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.